Circulating microRNAs have been described as head and neck cancer biomarkers in multiple anatomical subsites including the oral cavity, nasopharynx, larynx, salivary glands and the skin. While there is an expanding volume of published literature showing the significance of individual or panels of microRNAs, the clinical validation of candidate biomarkers is lacking. The various methods used to collect, store, process and interpret these microRNAs are likely introducing bias and contributing to the inconsistent results. A systematic scoping review was conducted using PRISMA standards to identify published English literature between 2007 and 2018. Pubmed and EMBASE databases were searched using specific keyword combinations related to head and neck cancer, circulating samples (whole blood, plasma or serum) and microRNA. Following the title and abstract review, two primary authors appraised the articles for their suitability to include in the review based on the detail of methodological descriptions. Thirty suitable articles were identified relating to nasopharyngeal carcinoma, oral cavity, oropharyngeal and laryngeal squamous cell carcinoma as well as primary salivary gland malignancies. Comprehensive methodological analysis identified poor reporting of detailed methodology, variations in collection, storage, pre-processing, RNA isolation and relative quantification including normalisation method. We recommend standardising the pre-processing, RNA isolation, normalisation and relative quantitation steps at biomarker discovery phase. Such standardisation would allow for bias minimisation and effective progression into clinical validation phases.
MicroRNA Cancer Circulating Biomarkers Otolaryngology
This is a preview of subscription content, log in to check access.
Garnett Passé Rodney William Memorial Foundation (GPRWMF). Australia and New Zealand Head and Neck Cancer Society (ANZHNCS).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Munn Z et al (2018) Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol 18(1):143CrossRefPubMedPubMedCentralGoogle Scholar
Cinpolat O et al (2017) Comparison of microRNA profiles between benign and malignant salivary gland tumors in tissue, blood and saliva samples: a prospective, case-control study. Braz J Otorhinolaryngol 83(3):276–284CrossRefPubMedGoogle Scholar
Ricieri Brito JA et al (2010) Reduced expression of mir15a in the blood of patients with oral squamous cell carcinoma is associated with tumor staging. Exp Ther Med 1(1):217–221CrossRefPubMedPubMedCentralGoogle Scholar
Xu Y et al (2016) Expression of serum microRNA-378 and its clinical significance in laryngeal squamous cell carcinoma. Eur Rev Med Pharmacol Sci 20(24):5137–5142PubMedGoogle Scholar
Xu X et al (2018) Dynamic changes in plasma microRNAs have potential predictive values in monitoring recurrence and metastasis of nasopharyngeal carcinoma. BioMed Res Int 2018:7329195PubMedPubMedCentralGoogle Scholar
Yan Y et al (2017) Circulating miRNAs as biomarkers for oral squamous cell carcinoma recurrence in operated patients. Oncotarget 8(5):8206–8214CrossRefPubMedGoogle Scholar
Rabinowits G et al (2017) Comparative analysis of microRNA expression among benign and malignant tongue tissue and plasma of patients with tongue cancer. Front Oncol 7:191CrossRefPubMedPubMedCentralGoogle Scholar
Wei L, Mao M, Liu H (2016) Droplet digital PCR and qRT-PCR to detect circulating miR-21 in laryngeal squamous cell carcinoma and pre-malignant laryngeal lesions. Acta Oto-laryngologica 136(9):923–932CrossRefPubMedGoogle Scholar
Gourzones C et al (2013) Consistent high concentration of the viral microRNA BART17 in plasma samples from nasopharyngeal carcinoma patients—evidence of non-exosomal transport. Virol J 10:119CrossRefPubMedPubMedCentralGoogle Scholar
Hsu CM et al (2012) Circulating miRNA is a novel marker for head and neck squamous cell carcinoma. Tumour Biol 33(6):1933–1942CrossRefPubMedGoogle Scholar
Ries J et al (2017) Prognostic significance of altered miRNA expression in whole blood of OSCC patients. Oncol Rep 37(6):3467–3474CrossRefPubMedGoogle Scholar
Lerner C et al (2016) Characterization of miR-146a and miR-155 in blood, tissue and cell lines of head and neck squamous cell carcinoma patients and their impact on cell proliferation and migration. J Cancer Res Clin Oncol 142(4):757–766CrossRefPubMedGoogle Scholar
Ries J et al (2014) Alterations in miRNA expression patterns in whole blood of OSCC patients. In vivo 28(5):851–861PubMedGoogle Scholar
Ries J et al (2014) miR-186, miR-3651 and miR-494: potential biomarkers for oral squamous cell carcinoma extracted from whole blood. Oncol Rep 31(3):1429–1436CrossRefPubMedGoogle Scholar
Sun G et al (2018) miR-200b-3p in plasma is a potential diagnostic biomarker in oral squamous cell carcinoma. Biomarkers 23(2):137–141CrossRefPubMedGoogle Scholar
Liu N et al (2014) A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma. Int J Cancer 134(6):1359–1368CrossRefPubMedGoogle Scholar